Reuters

AstraZeneca buys rare disease drugmaker Caelum in potential $500 mln deal

Alexion will pay $150 million to Caelum Plus up to $350 mln milestone-based future payments Sept 29 (Reuters) - AstraZeneca (AZN.L), opens new tab will take full control of Caelum Biosciences in a ...
Nasdaq

Caelum Biosciences Announces Collaborations with the Amyloidosis Advocacy Community and Support of Amyloidosis Awareness Month

BORDENTOWN, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases, today ...
FierceBiotech

Alexion bags option on Caelum to boost hematology franchise

Alexion has gained an option to buy Caelum Biosciences for its light chain (AL) amyloidosis candidate. The deal sees Alexion take an equity stake in the Fortress Biotech subsidiary and commit to a ...
Yahoo Finance

Fortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca to Fully Acquire Caelum Biosciences, a Company Founded by Fortress Biotech

NEW YORK and BORDENTOWN, N.J., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and ...
Business Wire

Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021

BORDENTOWN, N.J. & BOSTON--(BUSINESS WIRE)--Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced new Phase 2 safety and tolerability data for CAEL-101, a potentially ...